Profil
Dr. Harry Kopelman, MD, is Scientific Advisor at Easton Capital Investment Group.
Dr. Kopelman is a graduate of the Georgetown University School of Medicine, Washington, D.C.
(1980).
He completed his internship/residency at North Carolina Memorial Hospital/University of North Carolina, Chapel Hill (1983).
His fellowship in Cardiovascular Disease and Cardiac Electrophysiology was at the Vanderbilt University School of Medicine in Nashville, TN (1985).
Anciens postes connus de Harry Kopelman
| Sociétés | Poste | Fin |
|---|---|---|
Arterain Medical, Inc.
Arterain Medical, Inc. Medical SpecialtiesHealth Technology Develops medical devices to treat large vessel acute ischemic strokes | Directeur/Membre du Conseil | - |
Easton Capital Investment Group
Easton Capital Investment Group Investment ManagersFinance Easton invests in all segments of the healthcare industry, including biopharmaceuticals, drug delivery, medical devices and healthcare services. The firm is stage-agnostic and considers opportunities from early-stage venture capital to later-stage growth capital with investment size ranging from $0.05 - $10 million. They are generally not a seed-stage investor. | Corporate Officer/Principal | - |
Formation de Harry Kopelman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Arterain Medical, Inc.
Arterain Medical, Inc. Medical SpecialtiesHealth Technology Develops medical devices to treat large vessel acute ischemic strokes | Health Technology |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Easton Capital Investment Group
Easton Capital Investment Group Investment ManagersFinance Easton invests in all segments of the healthcare industry, including biopharmaceuticals, drug delivery, medical devices and healthcare services. The firm is stage-agnostic and considers opportunities from early-stage venture capital to later-stage growth capital with investment size ranging from $0.05 - $10 million. They are generally not a seed-stage investor. | Finance |
















